Loading…
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $3M | $-103M | $-115M | $-94M | -60.8% | -38.2% | 11.7% |
| 2024 | $5M | $-89M | $-103M | $-73M | -57.6% | -20.7% | -6.7% |
| 2023 | $6M | $-95M | $-111M | $-65M | -62.8% | -0.5% | 5.4% |
| 2022 | $6M | $-91M | $-105M | $-98M | -38.2% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 5.75 | 5.72 | 4.53 | 2.80 |
| Operating Revenue | - | 5.75 | 5.72 | 4.53 | 2.80 |
| Operating Expense | - | 112.50 | 99.90 | 113.42 | 128.22 |
| Research And Development | - | 58.91 | 48.07 | 63.86 | 81.42 |
| Selling General And Administration | - | 40.55 | 37.83 | 36.17 | 35.06 |
| Total Expenses | - | 112.50 | 99.90 | 113.42 | 128.22 |
| Operating Income | - | -106.75 | -94.18 | -108.89 | -125.42 |
| Total Operating Income As Reported | - | -106.75 | -115.52 | -108.89 | -120.32 |
| EBITDA | - | -91.29 | -95.46 | -89.08 | -103.16 |
| Normalized EBITDA | - | -91.29 | -74.12 | -89.08 | -108.26 |
| EBIT | - | -104.39 | -109.46 | -102.47 | -114.90 |
| Interest Expense | - | 0.97 | 1.01 | 0.56 | 0.21 |
| Net Interest Income | - | -0.97 | -1.01 | -0.56 | -0.21 |
| Other Non Operating Income Expenses | - | 2.36 | 6.06 | 6.42 | 5.41 |
| Other Income Expense | - | 2.36 | -15.28 | 6.42 | 10.51 |
| Interest Expense Non Operating | - | 0.97 | 1.01 | 0.56 | 0.21 |
| Net Non Operating Interest Income Expense | - | -0.97 | -1.01 | -0.56 | -0.21 |
| Pretax Income | - | -105.36 | -110.47 | -103.04 | -115.11 |
| Tax Provision | - | -0.46 | 0.10 | 0.07 | 0.07 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -4.48 | 0 | 1.07 |
| Net Income Continuous Operations | - | -104.90 | -110.57 | -103.11 | -115.18 |
| Net Income From Continuing And Discontinued Operation | - | -104.90 | -110.57 | -103.11 | -115.18 |
| Net Income From Continuing Operation Net Minority Interest | - | -104.90 | -110.57 | -103.11 | -115.18 |
| Net Income | - | -104.90 | -110.57 | -103.11 | -115.18 |
| Net Income Common Stockholders | - | -104.90 | -110.57 | -103.11 | -115.18 |
| Net Income Including Noncontrolling Interests | - | -104.90 | -110.57 | -103.11 | -115.18 |
| Normalized Income | - | -104.90 | -93.71 | -103.11 | -119.21 |
| Diluted NI Availto Com Stockholders | - | -104.90 | -110.57 | -103.11 | -115.18 |
| Basic Average Shares | - | 90.85 | 92.03 | 110.24 | 136.78 |
| Diluted Average Shares | - | 90.85 | 92.03 | 110.24 | 136.78 |
| Reconciled Depreciation | - | 13.10 | 14 | 13.39 | 11.74 |
| Total Unusual Items | - | 0 | -21.34 | 0 | 5.10 |
| Total Unusual Items Excluding Goodwill | - | 0 | -21.34 | 0 | 5.10 |
| Preferred Stock Dividends | 2.28 | - | - | - | - |
| Special Income Charges | - | 0 | -21.34 | 0 | 5.10 |
| Impairment Of Capital Assets | - | 0 | 21.34 | 0 | - |
| Restructuring And Mergern Acquisition | - | - | - | 0 | -5.10 |
| Depreciation Amortization Depletion Income Statement | - | 13.04 | 14 | 13.39 | 11.74 |
| Depreciation And Amortization In Income Statement | - | 13.04 | 14 | 13.39 | 11.74 |
| Otherunder Preferred Stock Dividend | 0 | - | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Absci Corporationthis co. | ABSI | $1.1B | -9.94 | 6.04 | -60.8% | -10.95 |
| Kestra Medical Technologies, Ltd. | KMTS | $1.2B | -10.49 | 5.81 | -55.4% | -10.21 |
| AMN Healthcare Services, Inc. | AMN | $1.2B | - | 1.85 | -14.9% | 19.35 |
| Schrödinger, Inc. | SDGR | $1.2B | -11.47 | 3.25 | -28.4% | -6.61 |
| Wave Life Sciences Ltd. | WVE | $1.2B |
| - |
| - |
| - |
| - |
| - |
| - |
| 2.26 |
| -39.4% |
| - |
| Avanos Medical, Inc. | AVNS | $1.2B | - | 1.50 | -9.4% | - |
| Zenas BioPharma, Inc. | ZBIO | $1.2B | -3.07 | 4.79 | -156.0% | -2.84 |
| OPKO Health, Inc. | OPK | $1.1B | -4.88 | 0.87 | -17.8% | -27.38 |
| Aktis Oncology, Inc. | AKTS | $1.1B | -17.25 | -7.52 | 43.6% | -14.83 |
| Peer Median | - | -10.49 | 2.05 | -23.1% | -8.41 | |